11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 27.09.2026 Expectation: 4650 pips
Invest in USDJPY up to its all-time high of 164.00
Today at 10:28 AM 29
Period: 30.09.2026 Expectation: 500 pips
Sell ​​GBPUSD down to 1.3540
Today at 09:22 AM 14
Gold buy
Period: 10.09.2026 Expectation: 300 pips
Buy gold with $4,900 in sight
Today at 06:54 AM 19
Period: 30.09.2026 Expectation: 250 pips
Buying EURUSD from 1.1650
Yesterday at 10:15 AM 27
Gold buy
Period: 30.09.2026 Expectation: 2500 pips
Invest in gold from $4,550
Yesterday at 10:15 AM 27
Brent sell
Period: 30.09.2026 Expectation: 250 pips
Brent crude sell-off targets $88.50
24 August 2026 46
Go to forecasts